C3 treats first European patient with CellSpray

Tissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has treated a first European patient with its burns therapy CellSpray at Halle, in Germany.

CellSpray is intended for use in patients with between 30 per cent and 90 per cent of injuries to the body surface. It was launched in Europe in September, at the European Burns Association meeting in Portugal. Surgeons and medical practitioners in 20 hospitals in German speaking countries have been trained in using the CellSpray technology.

In July, the first patient was treated with C3's CellSpray XP, which is intended for use in patients with injuries of 10 to 30 per cent of the body.

CellSpray is available for sale in Austria, Denmark, Germany, The Netherlands and the UK, while CellSpray XP is also available for sale in Switzerland and Italy.